Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Oxaliplatin followed by Gemcitabine and Radiation in Resected Pancreatic Cancer
NCT00191568Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2002
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by Eli Lilly and Company. Primary endpoints: Recurrence free one year survival at 1 year, Time to disease progression and 1 more. Started Oct 2002; status: completed.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00191568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191568.